News

Lymphoma Drug, AMD3100, Shows Promise in a Mouse Model of ALS

A recent study in mice could provide the first step toward a new way of treating amylotrophic lateral sclerosis (ALS). The research report, “Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS,“ was published on May 26 in the Journal of Neuroinflammation. In…

Study Examines Skeletal Muscle Remodeling in ALS and Potential Disease Biomarkers

Researchers investigating the processes of muscle degeneration and regeneration in people with amyotrophic lateral sclerosis (ALS) gained new knowledge of the pathways involved in muscle denervation and reinnervation. Specifically, they examined how proliferation and differentiation of skeletal muscle stem cells are affected by ALS, and potential biomarkers for disease progression. The study, “Skeletal Muscle Remodelling…

New ALS Research Featured at AAN 2016

The American Academy of Neurology Annual Meeting(AAN 2016), in Vancouver, British Columbia, featured significant advances in the understanding and treatment of amyotrophic lateral sclerosis (ALS). Among presentations at the April event, were ALS focused studies conducted by Dr. Sara van Mossevelde, Dr. Adriano Chio, Dr. Lindsey Hayes, Dr.

Study Finds Higher Pesticide Levels in Blood of Some ALS Patients, But No Definitive Link

New research reports that environmental pollutants appear to influence the risk of developing amyotrophic lateral sclerosis (ALS). The study, “Association of Environmental Toxins With Amyotrophic Lateral Sclerosis,” was published in JAMA Neurology by University of Michigan researchers working on pesticide and other environmental exposures. “From the first ALS patient I…